Astrazeneca PLC (AZN) Receives $38.69 Consensus Price Target from Analysts
Astrazeneca PLC (NYSE:AZN) has been assigned an average rating of “Hold” from the twenty-five analysts that are currently covering the stock. Three investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $38.69.
Several equities research analysts recently commented on the stock. Bank of America Corp. set a $41.40 price target on shares of Astrazeneca PLC and gave the stock a “buy” rating in a report on Thursday, September 8th. Argus raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Monday, August 29th. Piper Jaffray Cos. assumed coverage on shares of Astrazeneca PLC in a report on Friday, September 23rd. They issued an “overweight” rating for the company. BNP Paribas lowered shares of Astrazeneca PLC from an “outperform” rating to a “neutral” rating in a report on Tuesday, September 13th. Finally, Berenberg Bank reissued a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC boosted its position in Astrazeneca PLC by 45.2% in the first quarter. TIAA CREF Investment Management LLC now owns 398,366 shares of the company’s stock worth $11,218,000 after buying an additional 124,066 shares during the last quarter. Teachers Advisors Inc. boosted its position in Astrazeneca PLC by 595.6% in the first quarter. Teachers Advisors Inc. now owns 510,989 shares of the company’s stock worth $14,389,000 after buying an additional 437,531 shares during the last quarter. Franklin Resources Inc. boosted its position in Astrazeneca PLC by 89.8% in the first quarter. Franklin Resources Inc. now owns 2,026,200 shares of the company’s stock worth $57,058,000 after buying an additional 958,821 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Astrazeneca PLC by 118.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 11,230 shares of the company’s stock worth $316,000 after buying an additional 6,081 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock worth $65,485,000 after buying an additional 6,027 shares during the last quarter. 11.39% of the stock is currently owned by institutional investors.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 30.59 on Monday. The company has a market cap of $77.39 billion, a price-to-earnings ratio of 34.96 and a beta of 0.75. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The stock has a 50 day moving average of $32.87 and a 200 day moving average of $30.88.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.07. The firm earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.21 EPS. Equities research analysts predict that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.